BioXcel Therapeutics, Inc. - Special Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : So I have 3 questions. First, what specifically happens to patients after the response wears off? Do the patients get quickly agitated again? I'm asking because this product will be administered in the caregiver setting. So I'm trying to get a quantitative sense of how long the patient needs to remain in that setting after taking this product.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Got it. And then I'll ask my next 2 all in one shot. So the first part is, do you have any quantitative or qualitative details on what fraction of the patients in the trials in these 2 indications were between the ages of 55 and 75? And how the product performed in efficacy and safety in this age group? Because we're all trying to get a read-through to dementia here. And the second question is on a filing strategy, can you confirm that your first filed NDA for 501 will be in schizophrenia and bipolar disorder? And how you're thinking about that as there's a potential to accelerate approval in the COVID-19 delirium indication with other indications to follow as sNDAs?

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : Congrats on the data. First question, I wanted to go back to the prior comment on pursuing both doses commercially. Could you expand on what other factors that physicians will be considering since the safety between the 2 doses look fairly similar?

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : I see. Okay. And my other question is the dosing in the Alzheimer Phase I/II study. Could you remind us what the highest dose that study could go up to? And considering that it's an adapted design, you could exceed the doses that's currently in the clinical study, is that correct?

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : I'm talking about the ongoing Alzheimer's study.

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : So the Phase III dose could end up being the same as the doses in the schizophrenia and bipolar studies?